Eiden J J, Mouzinho A, Lindsay D A, Glass R I, Fang Z Y, Taylor J L
Department of Pediatrics, Johns Hopkins, University School of Medicine, Baltimore, Maryland 21205.
J Clin Microbiol. 1994 Jun;32(6):1599-603. doi: 10.1128/jcm.32.6.1599-1603.1994.
Recombinant major inner capsid protein (VP6) of the IDIR strain of group B rotavirus (GBR) was incorporated in a solid-phase immunoassay to access antibody response to infection in humans. Expression of VP6 in insect cells permitted design of a highly sensitive assay that avoided the contaminants present in GBR antigens obtained from fecal specimens. Among patients infected with the ADRV strain of GBR in China, increased reactivity with recombinant VP6 was observed in convalescent-phase sera in comparison with sera obtained shortly after infection (P = 0.0084). Anti-VP6 antibodies were detectable as soon as 7 days after onset of gastrointestinal symptoms, and serum reactivity persisted in specimens drawn more than 1 year after infection. Solid-phase immunoassay with recombinant VP6 was next employed in order to assess anti-GBR antibody in 513 serum specimens obtained from 423 Maryland residents (ages, 7 months to 96 years; median age, 42 years). Four individuals (< 1%) exhibited serum antibodies directed against the recombinant VP6 (ages, 54 to 95 years; mean age, 77 years). Examination of 129 additional serum specimens including some from other geographic regions of the United States failed to reveal the presence of anti-GBR antibody. Anti-GBR antibody was also not detected in any of 131 serum specimens from 60 staff and residents of a nursing home in Switzerland. While infection of humans with GBR has been uncommon in these locations outside of China, the detection of serum antibodies in older individuals in the United States either indicated an unknown, age-related risk factor or may have indicated infection in the more distant past. The availability of these reagents should allow surveys for GBR infection among additional populations that have not previously been investigated.
B组轮状病毒（GBR）IDIR株的重组主要内衣壳蛋白（VP6）被用于固相免疫测定，以检测人类对感染的抗体反应。VP6在昆虫细胞中的表达使得能够设计一种高灵敏度的测定方法，避免了从粪便标本中获得的GBR抗原中存在的污染物。在中国感染GBR ADRV株的患者中，与感染后不久获得的血清相比，恢复期血清中与重组VP6的反应性增加（P = 0.0084）。胃肠道症状出现后7天即可检测到抗VP6抗体，感染后1年以上采集的标本中血清反应性持续存在。接下来采用重组VP6固相免疫测定法，以评估从423名马里兰州居民（年龄7个月至96岁；中位年龄42岁）获得的513份血清标本中的抗GBR抗体。4人（<1%）表现出针对重组VP6的血清抗体（年龄54至95岁；平均年龄77岁）。对另外129份血清标本进行检测，包括一些来自美国其他地理区域的标本，未发现抗GBR抗体。在瑞士一家养老院的60名工作人员和居民的131份血清标本中，也未检测到抗GBR抗体。虽然在中国以外的这些地区，人类感染GBR并不常见，但在美国老年人中检测到血清抗体，要么表明存在未知的、与年龄相关的危险因素，要么可能表明在更遥远的过去曾有过感染。这些试剂的可用性应有助于对以前未调查过的其他人群进行GBR感染调查。
